Related Experiment Video

Updated: May 12, 2026

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Amylin uncovered: a review on the polypeptide responsible for type II diabetes

Karen Pillay1, Patrick Govender

  • 1Department of Biochemistry, School of Life Sciences, University of KwaZulu Natal, Westville Campus, Block F3, University Road, Private Bag X54001, Durban 4000, South Africa.

Biomed Research International
|April 23, 2013
PubMed

Insights

Amylin aggregation causes type II diabetes by forming toxic nanoparticles that destroy pancreatic beta-cells. Further research into amylin

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Neuroscience

Background:

  • Type II diabetes is increasingly prevalent, potentially linked to lifestyle factors.
  • Amylin, a key player in type II diabetes, forms toxic aggregates.
  • Unlike amyloid beta-peptide in Alzheimer's, amylin's role is under-researched.

Purpose of the Study:

  • To highlight amylin's critical role in type II diabetes pathogenesis.
  • To encourage further research into amylin's toxicity and inhibition.
  • To address the severe public health impact of type II diabetes complications.

Main Methods:

  • Characterization of amylin aggregate properties.
  • Investigation of amylin-induced toxicity mechanisms.
  • Evaluation of potential inhibitors of amylin toxicity.

Main Results:

  • Amylin aggregates into toxic nanoparticles, leading to beta-cell loss.
  • The mechanisms of amylin toxicity are complex and multifaceted.
  • Various inhibitors show potential in mitigating amylin toxicity.

Conclusions:

  • Amylin is a significant factor in type II diabetes, warranting more research.
  • Understanding amylin's aggregation and toxicity is crucial for developing treatments.
  • Inhibitors of amylin toxicity offer promising therapeutic avenues for type II diabetes.

More Related Videos

Isolation of Human Islets from Partially Pancreatectomized Patients11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...